Table 1.
Treatment strategies for NSCLC targeting RCD.
| Drugs | Treatment mechanism | Targeted RCD | Ref. |
|---|---|---|---|
| Baicalin | MCOLN3 activation and ROS accumulation | Autophagy-related apoptosis | (Dong et al.) |
| Berberine combined with icotinib | EGFR degradation and ROS accumulation | Apoptosis | (Chen et al.) |
| Aloe-emodin | MAPK signaling pathway and Akt/mTOR pathway | Apoptosis | (Shen et al.) |
| Vorinostat combined with gefitinib | HSP90/EGFR/MET/AKT | Apoptosis | (Park et al.) |
| Exopolysaccharides from the polar yeast Cryptococcus heimaeyensis | ROS/p38/ROS/ERK | Autophagy | (Hao et al.) |
| Polyphyllin VI | PI3K/AKT/mTOR | Autophagy and apoptosis | (Teng et al.) |
| Small molecule agonists targeting receptor-interacting protein kinase | Destroying lysosomal function and calcium ion balance | Necroptosis | (Garnique et al.) |
| (-)-Guaiol | Damage-associated molecular patterns (DAMPs) release | Immunogenic cell death and necroptosis | (Yang et al.) |
| Auranofin | TrxR1 inhibition and ROS accumulation; DAMPs release and dendritic cell activation | Ferroptosis | (Freire Boullosa et al.) |
| DE-Cu4O3 NPs | Mitochondrial dysfunction and telomerase inactivation | Cuproptosis | (Abu-Serie and Blasco) |
| Cucurbitacin B | TLR4/NLRP3/GSDMD/IL-1β | Pyroptosis | (Yuan et al.) |
| Sophflarine A | NLRP3/caspase-1/GSDMD | Pyroptosis and autophagy | (Luo et al.) |
| Reniformin A | TLR4/NLRP3 | Pyroptosis | (Zhu et al.) |
| Shikonin | COX-2/caspase-1/GSDME | Pyroptosis | (Cao et al.) |
| Iridium (III) complex | Endoplasmic Reticulum stress and ROS accumulation | Immunogenic cell death | (Wang et al.) |
| sea hare hydrolysates (SHH) | STAT3/ROS/caspase-1 | Immunogenic cell death and pyroptosis and necroptosis | (Nyiramana et al.) |
| Dihydroartemisinin (DHA) combined with cisplatin | ROS-endoplasmic reticulum stress-JNK/p38 MAPK cascade | Immunogenic cell death | (Ni et al.) |
| Evodiamine combined with cisplatin | Epigenetic regulation | Autophagy | (Panda et al.) |